stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Operating cash flow
NeoGenomics, Inc.'s operating cash flow for fiscal 2025 was $5.2M, down 25.5% from $7.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $4.3M. Over the past ten years it has ranged from −$66.0M (fiscal 2022) to $44.8M (fiscal 2018); the current reading is higher than 45% of that period. NeoGenomics, Inc. ranks 25th of 49 Diagnostics & Research companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $5.2M | (25.53%) |
| FY2024 | $7.0M | — |
| FY2023 | −$2.0M | — |
| FY2022 | −$66.0M | — |
| FY2021 | −$26.7M | — |
| FY2020 | $1.5M | (93.75%) |
| FY2019 | $23.4M | (47.82%) |
| FY2018 | $44.8M | 148.30% |
| FY2017 | $18.0M | (16.02%) |
| FY2016 | $21.5M | 235.95% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$8.9M | — |
| Jun 2026 | $20.0M | — |
| Mar 2026 | −$8.1M | — |
| Dec 2025 | $1.3M | (84.88%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| VCYT Veracyte, Inc. compare | $173.9M |
| CDNA CareDx, Inc. compare | $69.0M |
| CSTL Castle Biosciences, Inc. compare | $39.7M |
| NEO NeoGenomics, Inc. | $4.3M |
| FRNM Freenome, Inc compare | −$907.1K |
| ADPT Adaptive Biotechnologies Corporation compare | −$4.3M |
| WGS GeneDx Holdings Corp. compare | −$48.7M |
| PSNL Personalis, Inc. compare | −$97.6M |
| OPK OPKO Health, Inc. compare | −$125.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement